pharmaphorum

MAY 20, 2022

After a non-committal appraisal of Big Health’s Sleepio app for insomnia last November in draft guidance from NICE, the cost-effectiveness agency has come out in favour of the digital therapy. The earlier draft guidance showed that NICE was uncertain whether Sleepio would save money for the NHS, but its latest document recommends the app as a cost-saving option for treating insomnia in primary care “for people who would otherwise be offered advice about sleep hygiene or sleeping pill

Documentation 119

Documentation 119

Outsourcing Pharma

MAY 20, 2022

The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, has awarded a total of $577m to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.

104

104

pharmaphorum

MAY 20, 2022

Several of the top pharmaceutical companies have joined a new coalition that aims to improve access to cancer medicines in low- and lower-middle-income countries (LLMICs). The new initiative – called ATOM (Access to Oncology Medicines) – pledges to tackle the issue that fewer than 50% of the cancer medicines on the World Health Organization’s essential medicines list are available in developing nations around the world.

Pharmaceutical Companies 108

Pharmaceutical Companies Pharmaceutical Companies Hospitals 108

Pharma Times

MAY 20, 2022

Scientists demonstrated that AZD1236 halts oedema while reducing spinal cord breakdown at site of injury

48

48

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MAY 20, 2022

UK scientists are being denied from joining the €95 billion Horizon research funding programme as a dispute over the trade border in Northern Ireland gets increasingly acrimonious. The UK’s involvement in the Horizon Europe programme as an associate member was included in the Brexit ‘divorce’ deal with EU, but has not been finalised.

105

105

Pharma Manufacturing

MAY 20, 2022

Supply chain challenges and industry trends are spurring new business strategies

Packaging 40

Packaging 40

Pharma Times

MAY 20, 2022

Thousands usually prescribed sleeping pills could be offered app-based treatment

41

41

pharmaphorum

MAY 20, 2022

A long-running partnership between digital therapeutics (DTx) developer Sidekick Health and Pfizer has resulted in a new app to support patients with atopic dermatitis, which will start rolling out in Europe and Japan later this year. Sidekick specialises in developing gamified digital health apps. Its alliance with Pfizer has already led to the launch of a series of medication management and lifestyle software programmes aimed at five chronic diseases.

Patient Care 69

Patient Care 69

pharmaphorum

MAY 20, 2022

The primary care setting has garnered significant attention from industry stakeholders due to its promise in commercial research. Not only do these sites offer a wide array of patient knowledge and medical expertise, but they can also have great benefits for clinical trial recruitment. Primary care providers frequently have ongoing relationships with patients, giving them an in-depth understanding of which patients would be most well suited to certain clinical trials.

Medical Records 59

Medical Records Hospitals Vaccines 59

pharmaphorum

MAY 20, 2022

In February, Atara Biotherapeutics paused enrolment into a trial of a CAR-T cell therapy for mesothelioma after a patient death. Now, its partner Bayer has backed out of a partnership covering two mesothelin-directed CAR-Ts signed in 2020. Bayer licensed rights to the two CAR-Ts in a deal worth up to $670 million, including $60 million paid upfront, for one autologous CAR-T already in clinical testing and a second “off-the-shelf” candidate in preclinical testing.

52

52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA